PTO-1390 (Rev. 12-2004) through 3/31/2007, OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

ATTORNEY'S DOCKET NUMBER Le A 36 Z To be assigned

CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. PRIORITY DATE CLAIMED INTERNATIONAL FILING DATE **August 2, 2003** PCT/EP2004/008075 July 20, 2004 TITLE OF INVENTION **Bicyclic Indolinesulphonamide Derivatives** APPLICANT(S) FOR DO/EO/US Dittrich-Wengenroth, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items 3. (5), (6), (9) and (21) indicated below. |X|The US has been elected (Article 31). X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. **X** An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). X Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 1) Certificate of Mailing under 37 C.F.R. 1.10; and Other items or information: 2) Itemized Return Receipt Postcard.

AP5 Rec'd PCT/PTO 2 7 JAN 2006. 12-2004)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

è

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.						Le A 36 734		
To be a signed 566340 PCT/EP2004/008075  21. The following fees are submitted:						Applicant use	Office use only	
a) Basic national fee\$300.00						\$ 300.00		
<b>X</b> b) Examination fee						\$ 200.00		
X c) Search fee\$500.00						\$ 500.00		
TOTAL OF ABOVE CALCULATIONS = \$1000.00						\$ 1,000.00		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence								
listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.								
Total Sheets	Total Sheets Extra sheets		Number of each additional 50 or fraction thereof (round up to a whole number)					
- 100 =		/50 =	x \$250.00		250.00	\$		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).						\$		
CLAIMS	NUME	BER FILED	NUMBER EXTRA	RATE		\$		
Total claims	1	9 - 20 = 0		× \$5	0.00	\$		
Independent clai	ms	7 -3=	4	× \$20	00.00	\$ 800.00		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00						\$		
TOTAL OF ABOVE CALCULATIONS =						\$ 1,800.00		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.						\$		
SUBTOTAL =						\$ 1,800.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$		
TOTAL NATIONAL FEE =						\$ 1,800.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +						\$		
TOTAL FEES ENCLOSED =						\$ 1,800.00		
Amount to be refunded:							\$	
Amount to be charged							\$	
a. A check in the amount of \$ to cover the above fees is enclosed.								
b. Please charge my Deposit Account No. 13-3372 in the amount of \$ 1,800.00 to cover the above fees.  A duplicate copy of this sheet is enclosed.								
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-3372. A duplicate copy of this sheet is enclosed.								
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.								
Jeffrey M. Greenman						M. felleg	uro	
Bayer Pharmaceuticals Corporation				SIG	SIGNATURE () Susan M. Pellegrino			
400 Morgan Lane Susan West Haven, CT 06516 NAME						генедино		
	48,972							
						ON NUMBER		
5004 070	1200 (DEV. 12.200	<u> </u>	Page 2 o	<u> </u>				

Attorney's Docket No. Le A 36 734

## IAP5 Rec'd PCT/PTO 27 JAN 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dittrich-Wengenroth, et al.

Serial No.: [to be assigned] National Stage Filing of PCT/EP2004/008075

Filed: herewith

For: Bicyclic Indolinesulphonamide Derivatives

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

I hereby certify that the attached correspondence comprising: Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing under 35 U.S.C. 371 [IN DUPLICATE]  $\square$ Application Data Sheet under 37 C.F.R. 1.76  $\square$ **Preliminary Amendment** Original oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4))  $\square$ English Translation of the Application (35 U.S.C. 371(c)(2))  $\square$ Copy of the International Application as filed (35 U.S.C. 371(c)(2)) Copy of Published International Application, Number WO Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98 consisting of: 1) Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b)(2) 2) Form(s) PTO/SB/08A-B [substitute for form 1449/PTO] (37 C.F.R. 1.98(a)(b)) 3) Copies of Cited References (37 C.F.R. 1.98(d)) Other:  $\square$ Itemized Return Receipt Post Card is, on the date shown below, being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ED 475524299 US addressed to:

> Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

January 27, 2006

Susan M. Lulusus Signature of Person Certifying / Susan M. Pellegrino